Compare ORLA & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORLA | TWST |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 5.2B |
| IPO Year | 2016 | 2018 |
| Metric | ORLA | TWST |
|---|---|---|
| Price | $9.79 | $90.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $21.00 | ★ $46.88 |
| AVG Volume (30 Days) | ★ 3.3M | 2.2M |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.12% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,572,000.00 |
| Revenue This Year | $63.44 | $18.91 |
| Revenue Next Year | N/A | $15.07 |
| P/E Ratio | $107.37 | ★ N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $9.15 | $23.30 |
| 52 Week High | $21.98 | $105.47 |
| Indicator | ORLA | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 40.55 | 56.55 |
| Support Level | $9.62 | $42.88 |
| Resistance Level | $10.50 | $105.47 |
| Average True Range (ATR) | 0.41 | 6.98 |
| MACD | 0.10 | -1.42 |
| Stochastic Oscillator | 46.10 | 40.43 |
Orla Mining Ltd is a mineral exploration company. It is engaged in the acquisition and exploration of mineral properties. The company holds three gold projects: the Camino Rojo gold and silver project in Zacatecas State, the Musselwhite gold mine project located in Ontario and the South Railroad projects in Nevada, USA, and the Cerro Quema gold project in Panama. It conducts business activities in Mexico, Panama, the United States, and Canada.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.